Thermo Fisher Scientific has signed an agreement with Mainz Biomed to develop and launch a next-generation colorectal cancer ...

For example, their much smaller peer, Mainz Biomed (NASDAQ: MYNZ) just announced a new collaboration agreement aimed at ...

Thermo Fisher Scientific has signed an agreement with German molecular genetics company Mainz Biomed, the developer of ...

Mainz Biomed (MYNZ) announced a collaborative agreement with Thermo Fisher Scientific (TMO), through its subsidiary Life Technologies. The collaboration agreement will enable Mainz Biomed and Thermo ...

From clinical developments to an upcoming FDA trial anticipated in 2025, Mainz Biomed NV MYNZ, the molecular genetics diagnostic company, is making headway in growing its business on its path to ...

Mainz Biomed B.V. (MYNZ) has released an update. Mainz Biomed has announced a collaboration with Thermo Fisher Scientific to develop a ...

In September 2024, Mainz Biomed (MYNZ) announced feedback received from the FDA for the breakthrough device designation with the request to expand the current clinical data set with additional ...

In September 2024, Mainz Biomed announced encouraging feedback received from the FDA for the breakthrough device designation with the request to expand the current clinical data set with ...

This page features the latest news about the Mainz Biomed BV stock. Mainz Biomed Announces Collaboration with Fugene Genetics in Israel Mainz Biomed NV (MYNZ) announces today its commercial ...

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit ...

The collaboration agreement will enable Mainz Biomed and Thermo Fisher to jointly develop and potentially commercialize Mainz Biomed’s Next Generation colorectal cancer screening product. The ...

In September 2024, Mainz Biomed announced encouraging feedback received from the FDA for the breakthrough device designation with the request to expand the current clinical data set with additional ...